

1 **Title:** Comparison of Peripheral Nerve Injury Outcomes Between COVID-19 Survivors and Non-COVID  
2 Rehabilitation Inpatients: A Retrospective Study

3

4 **Authors:** Antonio Mondríguez-González MD<sup>\*a</sup>; Brian M. Rothemich\* BS<sup>b</sup>; Manasi Sheth PhD<sup>a1</sup>; Kevin N.  
5 Swong<sup>c</sup>; Colin K. Franz MD, PhD<sup>a, d, e, f</sup>

6 a. Shirley Ryan Ability Lab: 355 E. Erie St, Chicago, IL 60611, USA

7 b. Virginia Commonwealth University School of Medicine: 1201 E Marshall St #4-100, Richmond,  
8 VA 23298, USA

9 c. Department of Neurological Surgery, Northwestern University, Feinberg School of Medicine: 420  
10 E Superior St, Chicago, IL 60611, USA

11 d. Department of Physical Medicine and Rehabilitation, Northwestern University Feinberg School of  
12 Medicine, Chicago IL: 420 E Superior St, Chicago, IL 60611, USA

13 e. Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of  
14 Medicine, Chicago IL: 420 E Superior St, Chicago, IL 60611, USA

15 f. Querrey Simpson Institute for Bioelectronics, Northwestern University Feinberg School of  
16 Medicine, Chicago IL: 303 E. Superior St, Chicago, IL 60611, USA

17 \*, denotes equal contribution by authors

18

19 **Short Running Title:** COVID-19 vs. Non-COVID PNI Outcomes

20 **Corresponding Author:** Colin K. Franz, Shirley Ryan AbilityLab, 26-North, 355 E. Erie Street, Chicago,  
21 IL 60611, USA; [cfranz@sralab.org](mailto:cfranz@sralab.org)

22

23

24

---

<sup>1</sup> Permanent address: 351 Evergreen Circle, Glendale Heights, IL 60139, USA

25 **Abstract**

26 **Introduction:** Peripheral nerve injury (PNI) is associated with severe Coronavirus disease 2019 (COVID-  
27 19) survivorship. The diagnosis of PNI is often made by a physiatrist during a detailed functional  
28 assessment during an inpatient rehabilitation stay. COVID-19 patients have elevated rates of medical  
29 comorbidities, including risk factors for acquired PNI, such as diabetes mellitus and obesity. It is not  
30 known if the functional prognosis from PNI in COVID-19 survivors differs substantially from PNI in other  
31 inpatient rehabilitation populations.

32 **Objective:** To determine the prognosis of PNI associated with severe COVID-19 survivorship and  
33 compare it to PNI associated with other inpatient rehabilitation populations.

34 **Design:** Retrospective chart review study.

35 **Setting:** Single-center inpatient rehabilitation hospital in a large urban city.

36 **Patients:** Adult patients admitted to an inpatient rehabilitation hospital with PNI(s).

37 **Interventions:** Not applicable.

38 **Main Outcome Measures:** The primary outcome was the change in manual muscle testing (MMT) over  
39 time. Secondary outcomes included the rate of peripheral nerve surgery and the number of distinct PNI  
40 sites per patient.

41 **Results:** The analysis consisted of 60 subjects with PNI. We identified 30 subjects who had PNI  
42 associated with COVID-19 and were matched with 30 subjects with PNI not associated with COVID-19  
43 who were diagnosed during their inpatient rehabilitation admission. The data collected included basic  
44 demographics, COVID-19 status immediately before inpatient rehabilitation admission, medical  
45 comorbidities, acute rehabilitation inpatient diagnosis, nerve injury location and mechanism of injury,  
46 muscles affected, and change in serial MMT, plus documentation of any surgical intervention. No  
47 significant difference was found between the improvement of MMT, surgery rate, or number of nerve  
48 injuries and COVID-19 status.

49 **Conclusion:** PNIs associated with severe COVID-19 survivorship have similar recovery patterns as those  
50 of other etiologies. This data is reassuring that PNI associated with COVID-19 may be managed similarly  
51 to other types of PNI.

52

53 **Introduction**

54 Coronavirus disease 2019 (COVID-19) has profoundly affected the world's health. As of August 2024,  
55 there have been 776 million confirmed disease cases.<sup>1</sup> Furthermore, multiple studies suggest that  
56 survivorship issues from COVID-19 include an array of PNIs. Overall, although a variety of risk factors  
57 have been associated with acquired PNI from severe COVID-19, little is known about the clinical  
58 outcomes of these patients. To make matters worse, COVID-19 has been associated with multiple  
59 mononeuropathies in the same patient. For example, our group recently described a case series involving  
60 66 PNIs found in 34 patients (average ~2 PNI/patient).<sup>2</sup> This association of PNI with COVID-19  
61 survivorship was noted early in the pandemic, including an observation that 12/83 post-COVID-19  
62 patients consecutively admitted for inpatient rehabilitation had an acquired PNI,<sup>2</sup> and just a few weeks  
63 later, a separate group described mononeuritis multiplex patterns in 11/69 COVID-19 patients  
64 consecutively admitted to an intensive care unit (ICU).<sup>3</sup> Irrespective to the COVID-19 pandemic, the rates  
65 of PNI worldwide are ill-defined. Still, the best estimates come from developed countries with national  
66 healthcare registries with rates between 11 to 14 cases per 100,000 population per year.<sup>4,5</sup> This is likely an  
67 underestimation of PNI incidence. For example, PNI can be an under-reported complication in the  
68 perioperative setting,<sup>6</sup> overlooked or missed in cases of complex polytrauma,<sup>7</sup> and in many countries like  
69 the United States that lack a national registry to study PNI; there are higher rates of PNI from gun  
70 violence.<sup>8</sup> Outcomes from PNI are known to be highly variable regardless of whether patients undergo  
71 nerve repair surgery.<sup>8</sup> Therefore, it is often challenging to prognosticate patient outcomes accurately. Prior  
72 studies have implicated age, site of injury, type of injury, and extent of vascular damage as the most  
73 important factors.<sup>8,9</sup>

74 Given the large numbers of people who survived severe COVID-19 and consequently were exposed to  
75 this risk for acquiring a PNI, the question of whether or not PNI outcomes are worse in survivors of severe  
76 COVID-19 is both important and unanswered. The purpose of this retrospective chart review study is to  
77 begin to define neurological recovery patterns and prognosis of PNIs associated with severe COVID-19  
78 versus other non-COVID-19 associations. Since we have access to a relatively large and chronic series  
79 of patients who acquired PNI in association with admission for acute COVID-19, we performed a  
80 retrospective study to compare their recovery patterns and outcomes in follow-up against those of non-

81 COVID-19 associated PNI identified from inpatient rehabilitation patients diagnosed and treated in an  
82 overlapping time frame.

### 83 ***Materials and Methods***

#### 84 *Study Subjects*

85 Study approval was granted by the Northwestern University Institutional Review Board. A total of 60  
86 subjects with a diagnosis of PNI were included in this study. PNI in the context of this study is defined as  
87 mononeuropathy caused by traumatic etiologies such as gunshots, puncture wounds, and high-impact  
88 collisions and nontraumatic etiologies such as entrapment/compression, critical illness, severe COVID-19  
89 survivorship, or medications leading to an impact on muscle strength and motor function. Subjects were  
90 selected from a registry of known PNI cases treated at the Shirley Ryan AbilityLab (an academic  
91 freestanding inpatient rehabilitation facility) in Chicago, IL (USA). Furthermore, subjects included in this  
92 study were equal to or greater than 18 years of age, and their PNI(s) must have been supported by  
93 electrodiagnostic studies. All subjects were patients admitted to inpatient rehabilitation who had their  
94 initial electrodiagnostic study and MMT conducted upon their rehabilitation hospital admission prior to  
95 their PNI being diagnosed. Subjects were placed into the post-COVID-19 PNI group if they acquired  
96 PNI(s) after admission to an acute care hospital for severe COVID-19 pneumonia. The post-COVID-19  
97 PNI group was admitted to inpatient rehabilitation due to generalized weakness and deconditioning as a  
98 result of severe COVID-19 survivorship and its associated hospital complications. Severe COVID-19  
99 survivorship was defined as recovery from an acute care hospitalization for COVID-19 requiring the use  
100 of assistive respiratory devices. Patients who were under the age of 18 or did not fit the rest of the  
101 inclusion criteria were excluded from data collection.

#### 102 *Study Outcomes*

103 The primary outcome of this retrospective study is to compare the improvement of MMT from the initial  
104 diagnosis and after-treatment interventions.<sup>10</sup> MMT was selected since it was well documented across  
105 patient charts and is a common clinical metric of peripheral nerve health. We were concerned that the  
106 improvement in MMT will be less in the post-COVID-19 group compared to other inpatient rehabilitation

107 patients (control group) due to the severity of their preceding illness, thus indicating a slower or reduced  
108 recovery process. The secondary outcome is to compare the surgery rate between these two groups.  
109 Due to the high rate of severe (axonotmesis) PNI associated with COVID-19,<sup>2</sup> we wondered if there may  
110 be a higher rate of nerve repair surgery within the post-COVID-19 group. The other secondary outcome is  
111 to compare the number of concomitant sites of PNI between the two groups. Since COVID-19 has been  
112 associated with mononeuritis multiplex patterns, we predicted that the post-COVID-19 group would be  
113 diagnosed with significantly more PNIs per patient.

#### 114 *Data Collection*

115 Data was collected by retrospectively reviewing patients' electronic medical records with PNI from July  
116 2018 to September 2023. A combination of electronic medical records from internal and external hospital  
117 systems was used to collect thorough data. We recorded several data points for each subject that  
118 consisted of age, race/ethnicity, whether or not the patient had COVID-19 before the PNI, comorbidities,  
119 acute rehabilitation inpatient status, mechanism of PNI, location of PNI, type of treatment intervention,  
120 electrodiagnostic studies at diagnosis, muscles affected by the PNI and their associated MMT scores at  
121 diagnosis and after treatment intervention. Each subject was screened for the following illnesses:  
122 diabetes mellitus, B12 deficiency, hypertension, hyperlipidemia, and obesity. The type of treatment was  
123 subdivided into no surgery, external neurolysis, direct nerve repair, nerve graft repair, and nerve transfer  
124 surgery. MMT grades were recorded with the standard 0-5 scale without modifiers (i.e., no 4+ or 4-). Only  
125 muscles tested during a documented physical exam and graded less than five were recorded at or within  
126 a month after initial electrodiagnostic studies. Follow-up MMT was done within 1 month of initial  
127 electrodiagnostic testing at either an outpatient or inpatient setting, depending on if the patient had been  
128 discharged from inpatient rehabilitation, although the latest available MMT was recorded for post-  
129 intervention data points within a maximum of two years of the start of the intervention (physical therapy,  
130 surgery).

131

132

133 *Data Preparation*

134 When analyzing MMT data, the 60 subjects were further broken down into the specific nerve-injured and  
135 the associated muscle groups innervated by the nerve. Each nerve was then listed with its associated  
136 pre-intervention and post-intervention MMT grades. Each PNI was then categorized into one of three  
137 groups: no improvement, small improvement, and large improvement. No improvement was given if the  
138 difference in muscle grades was “0”. Small improvement was given if the muscle grade improved by one  
139 MMT grade, except for a “4,” progressing into a “5” to mitigate against the ceiling effect. Large  
140 improvement was given if the muscle grade improved to a “5” or improved by two or more MMT grades.  
141 Furthermore, if a PNI was not confirmed by a corresponding muscle group with a pre-intervention and  
142 post-intervention manual muscle test, it was removed from the data set (e.g., lateral femoral cutaneous  
143 nerve). In addition, if two or more muscle groups were associated with the PNI, only the muscle group  
144 with the highest level of improvement was included in the data set. If there was a tie in improvement level,  
145 then the most proximal muscle group with respect to the lesion site was included in the data set when  
146 paired with the PNI.

147

148 *Statistical Analysis*

149 Following data collection and preparation, a Student’s t-test and several two-sided Fisher’s exact tests  
150 were appropriately used to determine the presence of a statistically significant difference between ages,  
151 sex, race/ethnicities, comorbidities, and mechanism of injury for the post-COVID-19 PNI versus other  
152 non-COVID-19 PNI. A p-value of 0.05 was used when testing the statistical significance.

153 A Mann-Whitney U test was used to evaluate whether improvement in strength grading from MMT (no  
154 improvement, small improvement, large improvement) significantly differs by the COVID-19 status of PNI  
155 (post-COVID-19 versus other non-COVID-19 associations). A p-value of 0.05 was used when testing the  
156 statistical significance.

157 A two-sided Fisher's exact test was used to determine if there was a significant association between  
158 treatment intervention and the COVID-19 status of PNI. A 2x2 contingency table was made to record the  
159 number of observations for treatment intervention (surgery versus no surgery) and the COVID-19 status  
160 of PNI (post-COVID-19 versus other non-COVID-19 associations). A p-value of 0.05 was used when  
161 testing the statistical significance.

162 A two-sided Fisher's exact test was used to determine if there was a significant association between the  
163 number of PNIs and post-COVID-19 status. A 2x2 contingency table was created to record the number of  
164 observations for each group. A p-value of 0.05 was used when testing the statistical significance.

### 165 *IRB and Data Storage*

166 This research study was approved by the Northwestern University IRB before data collection. Since this  
167 project is a retrospective chart review with no contact with subjects, no informed consent or waiver of  
168 consent was needed to gather and conduct research. All data documents with patient identifiers were  
169 encrypted and only available to the study investigators. All data was initially entered into a password-  
170 protected RedCap project database without patient identifiers. Before statistical analysis, all patient  
171 identifiers were removed from the final data collection document.

172

## 173 **Results**

### 174 *Demographics, Comorbidities, and Mechanism of Nerve Injury*

175 A total of 60 subjects were analyzed in this study. Of these patients with PNIs, 30 subjects belong to the  
176 post-COVID-19 PNI group, while the remaining 30 subjects with other non-COVID-19 PNI belong to the  
177 control group. A summary of their characteristics can be seen in Table 1. Statistically significant  
178 differences were noted between the post-COVID-19 PNI group and the control group in the prevalence of  
179 diabetes (COVID n=19/30, non-COVID-19 3/30, p=0.0001), and hypertension (COVID n=22/30, non-  
180 COVID-19 8/30, p=0.0007). In addition, other statistically significant differences were found between the  
181 post-COVID-19 PNI group and the control group in the ages (COVID 55.9±12.2, non-COVID-19

182 43.2±16.2,  $p=0.001$ ), and the Hispanic White racial/ethnicity group (COVID  $n=11/30$ , non-COVID-19  $2/30$ ,  
183  $p=0.010$ ). Lastly, the ratios of the mechanism of injury when comparing traumatic versus nontraumatic  
184 injuries proved to be statistically significant (COVID  $0:30$ , non-COVID-19  $19:11$ ,  $p=0.0001$ ). The ratios  
185 between sex, the remaining racial/ethnic groups, and obesity failed to reject the null hypothesis.

#### 186 *MMT Comparison Results*

187 Improvements in MMT data are summarized in Figure 1A. A Mann-Whitney U test was used to evaluate  
188 whether improvement in strength grading from MMT (no improvement, small improvement, large  
189 improvement) significantly differs by the COVID-19 status of PNI (post-COVID-19 versus other non-  
190 COVID-19 associations). The null hypothesis stated no significant difference exists between the  
191 improvements in manual muscle tests and the COVID-19 status of PNI. The results indicated no  
192 significant difference between the improvement in manual muscle tests and the COVID-19 status of PNI  
193 ( $z = 1.5195$ ,  $p = 0.1285$ ).

#### 194 *Surgery Comparison Results*

195 Surgical intervention data for each subject's PNI(s) is displayed in Table 1 and summarized in Figure 1B.  
196 We predicted that there would be a significantly higher surgery rate within the post-COVID-19 group, thus  
197 indicating that they require a more complicated recovery process due to the severity of the injuries. A  
198 Fisher's exact test was conducted to test the prediction that a significant association exists between  
199 treatment intervention and the COVID-19 status of PNI. The null hypothesis stated that no significant  
200 association exists between treatment intervention and the COVID-19 status of PNI. Using a 0.05 alpha,  
201 the null hypothesis failed to be rejected (two-tailed  $p = 0.1188$ ). Therefore, there is no significant  
202 association between treatment intervention (no surgery versus surgery) and the COVID-19 status of PNI  
203 (post-COVID-19 versus other non-COVID-19 associations).

#### 204 *Number of Nerve Injuries Comparison Results*

205 The number of nerve injuries for each subject is shown in Table 1 and summarized in Figure 1C. We  
206 predicted that there would be a significantly higher number of PNIs within the post-COVID-19 group. A



207 Fisher's exact test was conducted as outlined in the Materials and Methods section to test this prediction  
208 that there is a significant association between the number of PNIs and the COVID-19 status of the PNI.  
209 The null hypothesis stated that no significant association exists between the number of PNIs and the  
210 COVID-19 status of the PNI. Using a 0.05 alpha, the null hypothesis failed to be rejected (two-tailed  $p =$   
211 0.1188). Therefore, there is no significant association between the number of PNIs (one injury versus  
212 multiple injuries) and the COVID-19 status of the PNI (post-COVID-19 versus other non-COVID-19  
213 associations).

## 214 ***Discussion***

215 Severe COVID-19 survivorship is associated with PNIs. Many of these COVID-19-associated PNIs tend  
216 to be severe, primarily associated with axonal injuries, and even with proper medical care, lead to  
217 significant disability in many patients.<sup>2</sup> This prior data implied that COVID-19-associated PNIs may have  
218 less favorable outcomes than other types of PNIs. Upon initial evaluation, the COVID-19 PNI group had a  
219 statistically significant older sample and a higher presence of comorbidities such as diabetes and  
220 hypertension, as seen in Table 1. Older age, diabetes, and hypertension are risk factors for developing  
221 PNIs, while older age is a risk factor for poorer PNI prognosis.<sup>9</sup> However, our retrospective analysis  
222 revealed no significant associations between improvement in MMT and whether or not the PNI was  
223 associated with COVID-19. Our findings reassure us that COVID-19-associated PNI patients do not have  
224 substantially different outcomes. In addition, there were no differences in the need for surgical  
225 intervention or the number of PNI sites/patients and COVID-19. Together, these results indicate COVID-  
226 19 COVID-19-associated PNI patients do not appear to have inherently worse outcomes than non-  
227 COVID-19 PNI patients. These results support using existing treatment guidelines for PNIs in this specific  
228 patient population.

229 Severe COVID-19 patients appear to have an increased propensity for acquired PNI, and the potential  
230 reasons for this are likely multifactorial. Although the data is limited, in one neuropathological study of  
231 patients who died from COVID-19, muscle and nerve tissues exhibited signs of immune-mediated  
232 damage without direct infection by SARS-CoV-2, underscoring the impact of immune response rather  
233 than viral invasion in nerve injuries associated with the disease.<sup>11</sup> It appears that an interplay of

234 inflammatory and other immune-mediated factors results in a cytokine storm that directly damages nerve  
235 tissue and supporting vasculature,<sup>12,13,14,15</sup> combined with mechanical loading of nerves due to patient  
236 positioning while admitted in the ICU.<sup>16,17,18</sup> Indeed, our group previously noted that PNI localizations  
237 seemed heavily biased to sites of known vulnerability to mechanical loading from direct compression or  
238 traction mechanisms.<sup>2</sup>

239 PNI management can vary depending on whether they are open or closed injuries. Open injuries from  
240 traumatic mechanisms such as laceration or transection generally benefit from early surgical repair (re-  
241 anastomosis, grafting, etc.) when they are identified acutely. Meanwhile, closed injuries can be due to  
242 more diverse etiologies, from non-penetrating traumatic injury to chronic nerve entrapment injury, such as  
243 carpal tunnel syndrome.<sup>19</sup> Generally speaking, COVID-19-associated PNIs are closed injuries. Closed  
244 injuries require a thorough clinical assessment, usually including electrodiagnostic studies and serial  
245 reassessments, which can include advanced imaging with repeat electrodiagnostic studies and physical  
246 examination. If a closed PNI shows no signs of spontaneous axon regeneration, then patients may  
247 consider whether or not to undergo surgery, which may involve repair methods such as neurolysis,  
248 neuroma resection, and/or graft repair, as well as nerve transfer surgery.<sup>19</sup> Physical and/or occupational  
249 therapy is an essential part of the pre-rehabilitation and post-surgical rehabilitation process. Interestingly,  
250 despite the non-COVID-19 PNI group of our study containing many more traumatic mechanisms of injury,  
251 the rate of surgery used to manage these two patient groups was not statistically different. The  
252 significance of this finding is uncertain, given the retrospective nature of our study.

253 Since the recovery of COVID-19 patients with PNIs does not differ substantially from the control group, it  
254 appears that similar treatment algorithms may be applied to both groups. In addition to reinforcing current  
255 guidelines on PNI treatment management for severe COVID-19 survivors, this study should help  
256 rehabilitation physicians evaluate the prognosis of post-COVID-19 patients with PNIs. This study's findings  
257 suggest no difference in muscle strength recovery regardless of the mechanism of injury and association  
258 with severe COVID-19 survivorship. Ninety-two percent of patients with COVID-19-associated PNI gained  
259 back some level of muscle improvement, while 75% of other causes of PNI improved in motor deficits. A  
260 majority of patients experiencing motor improvement after PNI treatments is not unexpected and is in line

261 with multiple prior studies. For example, Kim et al. demonstrate that 73% of patients with thoracic outlet  
262 syndrome-associated motor deficits improved after appropriate treatment.<sup>8</sup> Furthermore, another study with  
263 107 patients with a variety of upper limb PNIs had a statistically significant improvement in all 107 patients'  
264 muscle strength after appropriate treatment.<sup>20</sup> Despite state-of-the-art treatments being made available to  
265 all PNI patients in this study, functional recoveries were near-universally incomplete.<sup>28</sup> Partial functional  
266 recovery of PNIs remains a significant burden of disability of post-ICU survivors, including those that  
267 develop PNIs after severe COVID-19 survivorship.<sup>21</sup> Although these PNIs associated with COVID-19  
268 remain primarily axonal,<sup>2</sup> no FDA-approved treatments are available to improve axon regeneration in this  
269 patient population. More clinical research should be conducted to find effective axonal regeneration  
270 treatments to reduce the functional disability of these patients.

271 Evaluation of the study samples revealed possible health disparities due to the overrepresentation of a  
272 socially disadvantaged population. In the COVID-19-associated PNI sample, the distribution of  
273 race/ethnicity was 33.3%, 23.3%, and 36.7% for non-Hispanic white, non-Hispanic Black/African  
274 American, and Hispanic white, respectively. According to the 2018-2022 United States Census, Chicago's  
275 distribution of race/ethnicity was 32.7%, 28.8%, and 29.0% for non-Hispanic white, non-Hispanic  
276 Black/African American, and Hispanic white, respectively.<sup>22</sup> The data demonstrates a large  
277 overrepresentation of patients who identify as Hispanic white in the severe COVID-19 PNI group. As seen  
278 in Table 1, a statistical analysis confirmed an overrepresentation of people who identify as Hispanic white  
279 in the COVID-19 PNI group. This overrepresentation could be due to a variety of factors. The Hispanic  
280 population in Chicago was the most likely ethnic group to work in essential and high-exposure jobs during  
281 the COVID-19 pandemic.<sup>23</sup> In addition, there are social and economic factors within this ethnic group that  
282 reduce their access to healthcare, thus increasing their chances of developing complications due to  
283 severe COVID-19 survivorship.<sup>24</sup> These risk factors and health disparities affiliated with COVID-19-  
284 associated PNI can be further investigated in a subsequent study.

285 It is important to recognize the scope of clinical impact this study has regarding the increased prevalence  
286 of PNIs in the study population. The rate of focal neuropathies associated with severe COVID-19  
287 survivorship at inpatient rehabilitation facilities is approximately 10% compared to approximately 0.5% in

288 general rehab patients over the same time period.<sup>2</sup> PNIs subject patients to a substantial amount of long-  
289 term disability due to sensorimotor deficits and chronic neuropathic pain. Considering the high prevalence  
290 of PNIs associated with COVID-19 in the inpatient rehabilitation setting, physicians can implement the  
291 results from this study by confirming the effectiveness of their own clinical practices and existing  
292 treatment guidelines for addressing PNIs.

### 293 ***Limitations***

294 The limitations need to be addressed before considering the full implications of this study. There is a  
295 relatively small sample of 60 subjects used in this study due to the limited number of qualifying subjects  
296 from a single healthcare facility. Both the smaller sample size and the location where the sample was  
297 collected reduce external validity; however, this study is still the largest single data set to report COVID-  
298 19 PNI long-term outcomes. In addition, since patient follow-ups occurred inconsistently and at varied  
299 time frames, the post-treatment MMT data was collected at different time intervals among the patients.  
300 Selection bias resulted from several patients or multiple muscle groups not being included in the MMT  
301 data analysis due to incomplete follow-up data. Incomplete follow-up data either resulted from patients  
302 not returning for follow-up visits entirely or follow-up visits only containing partial MMT data compared to  
303 their initial visit. These issues could potentially introduce bias by disproportionately increasing or  
304 decreasing the improvement in MMT for one or both groups. Lastly, due to the retrospective design of this  
305 study, outcome data for muscle strength improvement was limited to an outcome measure that is used  
306 routinely in clinical practice, such as MMT, rather than more objective and continuous data, such as  
307 torque production or electrophysical recordings.

### 308 ***Future Works***

309 Several of these limitations can be addressed in future extensions of this study. For example, a larger  
310 sample size could increase the power of the results. The inclusion of multiple hospital systems, such as  
311 collaboration with other hospitals within our geographical region, could increase the external validity of the  
312 results. Furthermore, we hope to include phrenic neuropathy data in future iterations of this study by  
313 tracking improvements in diaphragm thickness ratios. Lastly, a multivariable regression analysis might

314 reveal complex associations not outlined in this paper, such as manual muscle improvement associated  
315 with race, gender, number of nerve injuries, treatment intervention, and COVID-19 status of nerve injury.

316 **Conclusion**

317 This data is impactful to the medical community as there is no literature to our knowledge that outlines the  
318 prognosis of this particular study population. This research fills a gap in the literature by providing a better  
319 understanding of the prognosis of post-COVID-19 PNIs. Because the results suggest there is no  
320 significant difference in prognosis between PNIs and their COVID-19 status, it can be inferred that  
321 physicians should not treat the two groups differently.

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340 **References**

- 341 1. WHO Coronavirus (COVID-19) Dashboard. Accessed August 21, 2024. <https://covid19.who.int>
- 342 2. Franz CK, Murthy NK, Malik GR, et al. The distribution of acquired peripheral nerve injuries  
343 associated with severe COVID-19 implicate a mechanism of entrapment neuropathy: a  
344 multicenter case series and clinical feasibility study of a wearable, wireless pressure sensor. *J*  
345 *NeuroEngineering Rehabil.* 2022;19(1):108. doi:10.1186/s12984-022-01089-1
- 346 3. Needham E, Newcombe V, Michell A, Thornton R, Grainger A, Anwar F, Warburton E, Menon D,  
347 Trivedi M, Sawcer S. Mononeuritis multiplex: an unexpectedly frequent feature of severe COVID-  
348 19. *J Neurol.* 2021 Aug;268(8):2685-2689. doi: 10.1007/s00415-020-10321-8. Epub 2020 Nov 26.  
349 PMID: 33244712; PMCID: PMC7690651.
- 350 4. Murphy RNA, de Schoulepnikoff C, Chen JHC, et al. The incidence and management of  
351 peripheral nerve injury in England (2005-2020). *J Plast Reconstr Aesthet Surg.* 2023;80:75-85.  
352 doi:10.1016/j.bjps.2023.02.017
- 353 5. Asplund M, Nilsson M, Jacobsson A, von Holst H. Incidence of traumatic peripheral nerve injuries  
354 and amputations in Sweden between 1998 and 2006. *Neuroepidemiology.* 2009;32(3):217-228.  
355 doi:10.1159/000197900
- 356 6. Welch MB, Brummett CM, Welch TD, et al. Perioperative peripheral nerve injuries: a retrospective  
357 study of 380,680 cases during a 10-year period at a single institution. *Anesthesiology.*  
358 2009;111(3):490-497. doi:10.1097/ALN.0b013e3181af61cb
- 359 7. Stone L, Keenan MA. Peripheral nerve injuries in the adult with traumatic brain injury. *Clin Orthop*  
360 *Relat Res.* 1988;(233):136-144.
- 361 8. Kim DH, Cho YJ, Tiel RL, Kline DG. Outcomes of surgery in 1019 brachial plexus lesions treated  
362 at Louisiana State University Health Sciences Center. *J Neurosurg.* 2003;98(5):1005-1016.  
363 doi:10.3171/jns.2003.98.5.1005
- 364 9. Hundepool CA, Ultee J, Nijhuis TH, Houpt P; Research Group 'ZERO'; Hovius SE. Prognostic  
365 factors for outcome after median, ulnar, and combined median-ulnar nerve injuries: a prospective  
366 study. *J Plast Reconstr Aesthet Surg.* 2015 Jan;68(1):1-8. doi: 10.1016/j.bjps.2014.09.043. Epub  
367 2014 Sep 28. PMID: 25448370.

- 368 10. Compston A. Aids to the investigation of peripheral nerve injuries. Medical Research Council:  
369 Nerve Injuries Research Committee. His Majesty's Stationery Office: 1942; pp. 48 (iii) and 74  
370 figures and 7 diagrams; with aids to the examination of the peripheral nervous system. By  
371 Michael O'Brien for the Guarantors of Brain. Saunders Elsevier: 2010; pp. [8] 64 and 94 Figures.  
372 *Brain*. 2010;133(10):2838-2844. doi:10.1093/brain/awq270
- 373 11. Suh J, Mukerji SS, Collens SI, et al. Skeletal Muscle and Peripheral Nerve Histopathology in  
374 COVID-19. *Neurology*. 2021;97(8):e849-e858. doi:10.1212/WNL.0000000000012344
- 375 12. Zhang Y, Chen X, Jia L, Zhang Y. Potential mechanism of SARS-CoV-2-associated central and  
376 peripheral nervous system impairment. *Acta Neurol Scand*. 2022 Sep;146(3):225-236. doi:  
377 10.1111/ane.13657. Epub 2022 Jun 14. PMID: 35699161; PMCID: PMC9349396.
- 378 13. Tatal GURSOY G, YUKSEL H, MULKEM SIMSEK I, et al. Neurological Presentations in Patients with  
379 COVID-19 in Cytokine Storm. *Can J Neurol Sci J Can Sci Neurol*.:1-7. doi:10.1017/cjn.2021.247
- 380 14. Li Z, Liu T, Yang N, et al. Neurological manifestations of patients with COVID-19: potential routes  
381 of SARS-CoV-2 neuroinvasion from the periphery to the brain. *Front Med*. 2020;14(5):533-541.  
382 doi:10.1007/s11684-020-0786-5
- 383 15. De Sanctis P, Doneddu PE, Viganò L, Selmi C, Nobile-Orazio E. Guillain–Barré syndrome  
384 associated with SARS-CoV-2 infection. A systematic review. *Eur J Neurol*. 2020;27(11):2361-  
385 2370. doi:10.1111/ene.14462
- 386 16. Malik GR, Wolfe AR, Soriano R, Rydberg L, Wolfe LF, Deshmukh S, Ko JH, Nussbaum RP,  
387 Dreyer SD, Jayabalan P, Walter JM, Franz CK. Injury-prone: peripheral nerve injuries associated  
388 with prone positioning for COVID-19-related acute respiratory distress syndrome. *Br J Anaesth*.  
389 2020 Dec;125(6):e478-e480. Doi: 10.1016/j.bja.2020.08.045. Epub 2020 Sep 4. PMID:  
390 32948295; PMCID: PMC7473147
- 391 17. Miller C, O'Sullivan J, Jeffrey J, Power D. Brachial Plexus Neuropathies During the COVID-19  
392 Pandemic: A Retrospective Case Series of 15 Patients in Critical Care. *Phys Ther*.  
393 2021;101(1):pzaa191. doi:10.1093/ptj/pzaa191

- 394 18. Brugliera L, Filippi M, Del Carro U, et al. Nerve Compression Injuries After Prolonged Prone  
395 Position Ventilation in Patients With SARS-CoV-2: A Case Series. *Arch Phys Med Rehabil*.  
396 2021;102(3):359-362. doi:[10.1016/j.apmr.2020.10.131](https://doi.org/10.1016/j.apmr.2020.10.131)
- 397 19. Spinner RJ, Kline DG. Surgery for peripheral nerve and brachial plexus injuries or other nerve  
398 lesions. *Muscle Nerve*. 2000;23(5):680-695. doi:[10.1002/\(sici\)1097-4598\(200005\)23:5<680::aid-  
399 mus4>3.0.co;2-h](https://doi.org/10.1002/(sici)1097-4598(200005)23:5<680::aid-mus4>3.0.co;2-h)
- 400 20. Milicin C, Sîrbu E. A comparative study of rehabilitation therapy in traumatic upper limb peripheral  
401 nerve injuries. *NeuroRehabilitation*. 2018;42(1):113-119. doi:[10.3233/NRE-172220](https://doi.org/10.3233/NRE-172220)
- 402 21. Huebner EA, Strittmatter SM. Axon regeneration in the peripheral and central nervous systems.  
403 *Results Probl Cell Differ*. 2009;48:339-351. doi:[10.1007/400\\_2009\\_19](https://doi.org/10.1007/400_2009_19)
- 404 22. U.S. Census Bureau QuickFacts: Chicago city, Illinois. Accessed December 26, 2023.  
405 <https://www.census.gov/quickfacts/fact/table/chicagocityillinois/HSD410222>
- 406 23. Schnake-Mahl AS, Lazo M, Dureja K, Ehtesham N, Bilal U. Racial and ethnic inequities in  
407 occupational exposure across and between US cities. *SSM Popul Health*. 2021;16:100959.  
408 doi:[10.1016/j.ssmph.2021.100959](https://doi.org/10.1016/j.ssmph.2021.100959)
- 409 24. Pedraza L, Villela R, Kamatgi V, Cocuzzo K, Correa R, Lisigurski MZ. The Impact of COVID-19 in  
410 the Latinx Community. *HCA Healthc J Med*. 3(3):97-104. doi:[10.36518/2689-0216.1387](https://doi.org/10.36518/2689-0216.1387)



Subject Characteristics	COVID-19	Non-COVID	p-values (sig<0.05)
Age	55.9 ± 12.2	43.2 ± 16.2	<b>p=0.001</b>
Sex M:F	26:4 (n=30)	21:9 (n=30)	p=0.209
Race/Ethnicities	Non-Hispanic White 33.3% (10/30)	Non-Hispanic White 60.0% (18/30)	Non-Hispanic White: p=0.069
	Non-Hispanic Black/African American 23.3% (7/30)	Non-Hispanic Black/African American 16.7% (5/30)	Non-Hispanic Black/African American: p=0.748
	Hispanic White 36.7% (11/30)	Hispanic White 6.7% (2/30)	Hispanic White: <b>p=0.010</b>
	Unknown 6.7% (2/30)	Unknown 16.7% (5/30)	Unknown: p=0.437
Comorbidities	Diabetes 63.3% (19/30)	Diabetes 10.0% (3/30)	Diabetes: <b>p=0.0001</b>
	Obesity 43.3% (13/30)	Obesity 30.0% (9/30)	Obesity: p=0.422
	Hypertension 73.3% (22/30)	Hypertension 26.7% (8/30)	Hypertension: <b>p=0.0007</b>
Mechanism of Injury Traumatic:Nontraumatic	0:30 (n=30)	19:11 (n=30)	<b>p=0.0001</b>

411  
412

**Table 1. Subject Characteristics.** Significant p-values have been bolded.

413

414

415

416

417

418

419

420

(a)

<u>MMT Improvement</u>	<u>Cause of Neuropathy</u>	
	<b>COVID-19 Associated</b> (n=38)	<b>Other Causes</b> (n=36)
<b>No Improvement in Muscle Grade</b>	8% n=3	25% n=9
<b>Small Improvement in Muscle Grade</b>	16% n=6	17% n=6
<b>Large Improvement in Muscle Grade</b>	76% n=29	58% n=21

(b)

<u>Treatment Intervention</u>	<u>Cause of Neuropathy</u>	
	<b>COVID-19 Associated</b> (n=30)	<b>Other Causes</b> (n=30)
<b>No Surgery Treatment Intervention</b>	43% n=13	67% n=20
<b>Surgery Treatment Intervention</b>	57% n=17	33% n=10

(c)

<u>Number of Nerve Injuries</u>	<u>Cause of Neuropathy</u>	
	<b>COVID-19 Associated</b> (n=30)	<b>Other Causes</b> (n=30)
<b>One Nerve Injury</b>	33% n=10	57% n=17
<b>Multiple Nerve Injuries</b>	67% n=20	43% n=13

421

422 **Figure 1. Contingency Tables.** (a) MMT Improvement. Small Improvement: increase by one grade;  
 423 Large Improvement: increase to 5/5 or increase by two or more grades. (b) Number of Surgeries. (c)  
 424 Number of Nerve Injuries.  
 425

426

427

Record ID	Age	Sex	Race and Ethnicity	Mechanism of Nerve Injury	COVID	Diabetes	Obesity	Hypertension	Surgical Intervention	Number of Nerve Injuries
1	Over 65	Male	Non-Hispanic White	Nontraumatic	Yes	No	Yes	No	Yes	4
2	Over 65	Female	Non-Hispanic White	Nontraumatic	Yes	Yes	Yes	No	Yes	4
3	Over 65	Male	Non-Hispanic Black/African American	Nontraumatic	Yes	No	Yes	Yes	No	2
4	45-54	Male	Hispanic White	Nontraumatic	Yes	Yes	No	No	Yes	4
5	25-64	Male	Hispanic White	Nontraumatic	Yes	Yes	No	Yes	No	1
6	55-64	Male	Non-Hispanic White	Nontraumatic	Yes	Yes	Yes	Yes	No	1
7	55-64	Male	Non-Hispanic Black/African American	Nontraumatic	Yes	No	No	Yes	No	1
8	25-64	Male	Hispanic White	Nontraumatic	Yes	No	Yes	Yes	Yes	2
9	Over 65	Female	Non-Hispanic Black/African American	Nontraumatic	Yes	Yes	Yes	Yes	No	2
10	18-24	Female	Hispanic White	Nontraumatic	Yes	Yes	No	No	No	1
11	55-64	Male	Non-Hispanic Black/African American	Nontraumatic	Yes	Yes	No	Yes	No	2
12	45-54	Male	Hispanic White	Nontraumatic	Yes	Yes	No	Yes	Yes	2
13	25-44	Female	Hispanic White	Nontraumatic	Yes	No	Yes	Yes	Yes	1
14	55-64	Male	Non-Hispanic Black/African American	Nontraumatic	Yes	Yes	No	Yes	No	3
15	Over 65	Male	Non-Hispanic Black/African American	Nontraumatic	Yes	No	No	No	No	2
16	25-34	Male	Unknown	Nontraumatic	Yes	Yes	Yes	Yes	No	3
17	55-64	Male	Hispanic White	Nontraumatic	Yes	Yes	Yes	Yes	Yes	6
18	Over 65	Male	Hispanic White	Nontraumatic	Yes	No	Yes	Yes	No	4
19	Over 65	Male	Non-Hispanic White	Nontraumatic	Yes	No	No	No	No	1
20	Over 65	Male	Hispanic White	Nontraumatic	Yes	No	No	Yes	Yes	3
21	45-54	Male	Hispanic White	Nontraumatic	Yes	Yes	No	Yes	No	2
22	25-34	Male	Hispanic White	Nontraumatic	Yes	No	Yes	Yes	No	1
23	Over 65	Female	Non-Hispanic Black/African American	Nontraumatic	No	No	Yes	Yes	No	2
24	45-54	Female	Non-Hispanic White	Nontraumatic	No	No	No	Yes	No	2
25	45-54	Male	Non-Hispanic White	Traumatic	No	No	Yes	Yes	No	1
26	18-24	Male	Hispanic White	Nontraumatic	No	No	No	No	Yes	1
27	18-24	Female	Non-Hispanic White	Traumatic	No	No	No	No	Yes	1
28	55-64	Female	Non-Hispanic White	Nontraumatic	No	No	No	Yes	Yes	1
29	55-44	Male	Non-Hispanic White	Traumatic	No	Yes	No	No	Yes	4
30	Over 65	Male	Non-Hispanic White	Nontraumatic	Yes	Yes	No	Yes	No	4
31	45-54	Male	Non-Hispanic White	Nontraumatic	Yes	Yes	No	No	Yes	7
32	Over 65	Male	Non-Hispanic Black/African American	Nontraumatic	Yes	Yes	No	Yes	Yes	1
33	45-54	Male	Non-Hispanic White	Nontraumatic	Yes	Yes	No	Yes	No	2
34	55-64	Male	Non-Hispanic White	Nontraumatic	No	No	No	No	Yes	4
35	55-64	Male	Non-Hispanic White	Nontraumatic	No	No	No	No	Yes	5
36	Over 65	Male	Non-Hispanic White	Nontraumatic	Yes	Yes	Yes	Yes	Yes	3
37	25-34	Male	Non-Hispanic White	Traumatic	No	No	No	Yes	No	1
38	55-44	Male	Non-Hispanic Black/African American	Traumatic	No	No	No	No	No	1
39	55-44	Male	Non-Hispanic White	Traumatic	No	No	No	No	No	3
40	18-24	Female	Non-Hispanic White	Traumatic	No	No	No	No	No	1
41	18-24	Male	Non-Hispanic Black/African American	Traumatic	No	No	No	No	No	3
42	Over 65	Male	Non-Hispanic White	Traumatic	No	No	Yes	No	No	1
43	25-34	Male	Non-Hispanic Black/African American	Traumatic	No	No	No	No	No	1
44	25-34	Male	Hispanic White	Traumatic	No	No	No	No	No	1
45	25-44	Male	Unknown	Traumatic	No	No	Yes	No	No	1
46	18-24	Male	Unknown	Traumatic	No	No	No	No	No	5
47	55-64	Male	Non-Hispanic White	Nontraumatic	No	Yes	Yes	No	No	2
48	35-44	Female	Unknown	Traumatic	No	No	No	No	No	1
49	35-44	Female	Non-Hispanic White	Nontraumatic	No	No	Yes	Yes	Yes	1
50	15-44	Female	Non-Hispanic White	Nontraumatic	No	No	Yes	No	Yes	1
51	55-64	Male	Non-Hispanic White	Traumatic	No	No	No	Yes	No	1
52	Over 65	Male	Non-Hispanic Black/African American	Traumatic	No	Yes	No	No	No	1
53	18-24	Male	Non-Hispanic White	Traumatic	No	No	No	No	No	2
54	Over 65	Female	Non-Hispanic White	Nontraumatic	No	No	No	Yes	No	2
55	Over 65	Male	Non-Hispanic White	Nontraumatic	Yes	Yes	Yes	Yes	Yes	1
56	15-34	Male	Unknown	Nontraumatic	Yes	Yes	No	No	No	2
57	Over 65	Male	Non-Hispanic White	Nontraumatic	Yes	No	No	Yes	No	1
58	25-64	Male	Non-Hispanic White	Traumatic	No	No	No	No	No	3
59	55-64	Male	Unknown	Nontraumatic	No	No	Yes	No	No	1
60	25-34	Male	Unknown	Traumatic	No	No	Yes	No	Yes	3

428

429 **Table 2. Demographics, Comorbidities, and Nerve Injuries.**

430

431

432

433

434

435

Patient ID	Site of Nerve Injury	Grade Pre-Treatment Intervention	Grade Post-Treatment Intervention	No Improvement	Small Improvement	Large Improvement
1	Left Radial	2 (LWE)	5 (LWE)	No	No	Yes
2	Right Ulnar	3 (RFAB)	4 (RFAB)	No	Yes	No
2	Right Median	2 (RFF)	4 (RFF)	No	No	Yes
2	Right Radial	0 (REE)	5 (REE)	No	No	Yes
7	Right Upper Trunk	4 (REF)	5 (REF)	No	No	Yes
9	Left C8 Root	4 (LWF)	5 (LWF)	No	No	Yes
10	Left Deep Peroneal	1 (LADF)	4 (LADF)	No	No	Yes
11	Right Common Peroneal	0 (RAEV)	3 (RAEV)	No	No	Yes
12	Left Ulnar	2 (LFAB)	5 (LFAB)	No	No	Yes
12	Left Median	2 (LFF)	5 (LFF)	No	No	Yes
13	Right Upper Trunk	4 (REE)	5 (REE)	No	No	Yes
14	Right Spinal Accessory	1 (RSEL)	4 (RSEL)	No	No	Yes
14	Left Femoral	1 (LHF)	2 (LHF)	No	Yes	No
14	Left Obturator	4 (LHAD)	5 (LHAD)	No	No	Yes
16	Left Deep Peroneal	1 (LADF)	3 (LADF)	No	No	Yes
16	Right Deep Peroneal	1 (RADF)	3 (RADF)	No	No	Yes
17	Right Sciatic	0 (RAPF)	3 (RAPF)	No	No	Yes
17	Right Radial	0 (RWE)	3 (RWE)	No	No	Yes
18	Right Median	4 (REF)	4 (REF)	Yes	No	No
18	Right Upper Trunk	4 (REF)	4 (REF)	Yes	No	No
19	Right Common Peroneal	1 (RADF)	3 (RADF)	No	No	Yes
20	Right Femoral	2 (RHF)	5 (RHF)	No	No	Yes
20	Right Common Peroneal	1 (RADF)	4 (RADF)	No	No	Yes
21	Left C5 Root	3 (LEF)	4 (LEF)	No	Yes	No
22	Left Sciatic	4 (LKF)	5 (LKF)	No	No	Yes
23	Left Common Peroneal	0 (LGTE)	9 (LGTE)	No	No	Yes
24	Left Deep Peroneal	1 (LADF)	1 (LADF)	Yes	No	No
24	Left Sciatic	2 (LANF)	4 (LANF)	No	No	Yes
25	Left Lumbosacral Plexus	2 (LADF)	4 (LADF)	No	No	Yes
26	Left Radial	0 (LWE)	5 (LWE)	No	No	Yes
27	Right Common Peroneal	0 (RADF)	4 (RADF)	No	No	Yes
28	Left Sciatic	0 (LANF)	3 (LANF)	No	No	Yes
29	Right Posterior Cord	0 (RWE)	5 (RWE)	No	No	Yes
29	Right Middle Trunk	0 (REE)	5 (REE)	No	No	Yes
29	Right Upper Trunk	0 (REF)	5 (REF)	No	No	Yes
30	Left Median	4 (LTF)	5 (LTF)	No	No	Yes
30	Right Ulnar	3 (RFAB)	5 (RFAB)	No	No	Yes
31	Left Radial	0 (LWE)	1 (LWE)	No	Yes	No
31	Left Middle Trunk	0 (LWE)	1 (LWE)	No	Yes	No
31	Right Middle Trunk	0 (REE)	5 (REE)	No	No	Yes
31	Left Upper Trunk	2 (LEF)	3 (LEF)	No	Yes	No
31	Right Upper Trunk	0 (REF)	4 (REF)	No	No	Yes
32	Left Deep Peroneal	1 (LADF)	4 (LADF)	No	No	Yes
33	Right Common Peroneal	1 (RADF)	1 (RADF)	Yes	No	No
33	Left Common Peroneal	1 (LADF)	3 (LADF)	No	No	Yes
34	Left Upper Trunk	0 (LWF)	3 (LWF)	No	No	Yes
34	Left Middle Trunk	0 (LWE)	4 (LWE)	No	No	Yes
34	Left Lower Trunk	0 (LWF)	3 (LWF)	No	No	Yes
36	Right Upper Trunk	2 (REF)	5 (REF)	No	No	Yes
36	Right Radial	0 (RWE)	2 (RWE)	No	No	Yes
37	Left Suprascapular	2 (LSEK)	5 (LSEK)	No	No	Yes
38	Right Lateral Cord	2 (REF)	3 (REF)	No	Yes	No
39	Left C7 Root	0 (LFE)	2 (LFE)	No	No	Yes
39	Left C8 Root	2 (LFAD)	2 (LFAD)	Yes	No	No
39	Left Radial	0 (LWF)	2 (LWF)	No	No	Yes
40	Right Radial	0 (RWE)	1 (RWE)	No	Yes	No
42	Left Femoral	0 (LHF)	3 (LHF)	No	No	Yes
44	Right Radial	4 (REE)	5 (REE)	No	No	Yes
45	Right Deep Peroneal	4 (RADF)	5 (RADF)	No	No	Yes
46	Left Common Peroneal	0 (LADF)	1 (LADF)	No	Yes	No
47	Right Median	2 (RFF)	4 (RFF)	No	No	Yes
47	Right Ulnar	4 (RFAB)	1 (RFAB)	Yes	No	No
49	Left Radial	0 (LWE)	5 (LWE)	No	No	Yes
53	Right Sciatic	4 (RHF)	1 (RHF)	Yes	No	No
53	Left Common Peroneal	4 (LADF)	2 (LADF)	Yes	No	No
54	Left Sciatic	4 (LAPF)	4 (LAPF)	Yes	No	No
54	Left Femoral	1 (LHF)	0 (LHF)	Yes	No	No
55	Right Radial	0 (RWE)	2 (RWE)	No	No	Yes
58	Right Upper Trunk	0 (REF)	0 (REF)	Yes	No	No
58	Right Middle Trunk	0 (REE)	0 (REE)	Yes	No	No
58	Right Lower Trunk	0 (RFAD)	1 (RFAD)	No	Yes	No
59	Right Femoral	2 (RHF)	4 (RHF)	No	No	Yes
60	Right Upper Trunk	0 (REF)	1 (REF)	No	Yes	No
60	Right Middle Trunk	0 (REE)	5 (REE)	No	No	Yes

436  
437 **Table 3. Manual Muscle Testing.** Small Improvement (increase by one grade), Large Improvement  
438 (Increase to 5 or increase by two or more grades); (LSEL)/(RSEL)- left/right shoulder elevators,  
439 (LEF)/(REF)- left/right elbow flexors, (LEE)/(REE)- left/right elbow extensors, (LWF)/(RWF)- left/right wrist  
440 flexors, (LWE)/(RWE)- left/right wrist extensors, (LFF)/(RFF)- left/right finger flexors, (LFE)/(RFE)-  
441 left/right finger extensors, (LFAB)/(RFAB)- left/right finger abductors, (LTF)/(RTF)- left/right thumb flexors,  
442 (LHF)/(RHF)- left/right hip flexors, (LHAD)/(RHAD)- left/right hip adductors, (LKF)/(RKF)- left/right knee  
443 flexors, (LADF)/(RADF)- left/right ankle dorsiflexors, (LAPF)/(RAPF)- left/right ankle plantarflexors,  
444 (LAEV)/(RAEV)- left/right ankle evertors, (LGTE)/(RGTE)- left/right great toe extensors  
445